MedPath

FAES FARMA, SA

🇪🇸Spain
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

30

Active:14
Completed:15

Trial Phases

3 Phases

Phase 1:11
Phase 2:5
Phase 3:7

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (23 trials with phase data)• Click on a phase to view related trials

Phase 1
11 (47.8%)
Phase 3
7 (30.4%)
Phase 2
5 (21.7%)

A randomised, double-blind, double-dummy, multicentre, phase III, non inferiority trial of an oral mesalazine formulation in patients with active mild to moderate ulcerative colitis for the induction of remission.

Phase 3
Recruiting
Conditions
Ulcerative colitis
First Posted Date
2024-07-24
Last Posted Date
2025-06-01
Lead Sponsor
Faes Farma S.A.
Target Recruit Count
386
Registration Number
2023-509606-30-00
Locations
🇭🇺

Eszak-Budai Szent Janos Centrumkorhaz, Budapest XII, Hungary

🇭🇺

Csoeszi Endoszkopos Kft., Kecskemet, Hungary

🇭🇺

Heves Varmegyei Markhot Ferenc Oktatokorhaz Es Rendelointezet, Eger, Hungary

and more 85 locations

Efficacy and Safety of Hemorrane Plus Versus Hemorrane and Versus Placebo in Patients With Uncomplicated Haemorrhoids

Phase 3
Terminated
Conditions
Haemorrhoids Without Complication
Interventions
Drug: Placebo
Drug: Hemorrane plus
Drug: Hemorrane
First Posted Date
2023-03-29
Last Posted Date
2024-02-28
Lead Sponsor
Faes Farma, S.A.
Target Recruit Count
21
Registration Number
NCT05788497
Locations
🇪🇸

CAP Can Bou, Castelldefels, Barcelona, Spain

🇪🇸

CAP Corbera de Llobregat, Corbera de Llobregat, Barcelona, Spain

🇪🇸

CAPSBE Les Corts, L'Hospitalet de Llobregat, Barcelona, Spain

and more 10 locations

Study to Assess the Safety, Tolerability and Efficacy of Bilastine Ophthalmic Solution 0.6% in Children

Phase 3
Completed
Conditions
Allergic Conjunctivitis
Interventions
Drug: Placebo
First Posted Date
2021-03-23
Last Posted Date
2023-03-16
Lead Sponsor
Faes Farma, S.A.
Target Recruit Count
59
Registration Number
NCT04810390
Locations
🇪🇸

Hospital Universitario de Cruces, Barakaldo, Bizkaia, Spain

🇪🇸

Instituto Oftálmologico Quironsalud A Coruña, A Coruña, Spain

🇪🇸

Hospital Universitari German Trias i Pujol (HGTiP),, Badalona, Spain

and more 15 locations

Efficacy and Safety of Calcifediol vs Placebo in Subjects With Vitamin D Deficiency

Phase 2
Completed
Conditions
Vitamin D Deficiency
Vitamin D Insufficiency
Interventions
First Posted Date
2021-02-03
Last Posted Date
2023-09-15
Lead Sponsor
Faes Farma, S.A.
Target Recruit Count
674
Registration Number
NCT04735926
Locations
🇧🇬

MC-1-Sevlievo Ltd., Sevlievo, Bulgaria

🇧🇬

Diagnostic & Consultative Center "Sveta Anna" EOOD, Sofia, Bulgaria

🇧🇬

Individual Practice Ambulatory for Specialized Medical Care - Cardiology, Obstetrics and Gynecology, Sofia, Bulgaria

and more 52 locations

A Study Evaluating Bilastine Ophthalmic Solution 0.6% in the Conjunctival Allergen Challenge (Ora-CAC®) Model.

First Posted Date
2018-03-27
Last Posted Date
2023-03-16
Lead Sponsor
Faes Farma, S.A.
Target Recruit Count
228
Registration Number
NCT03479307
Locations
🇺🇸

Cornea Consultants of AZ, Phoenix, Arizona, United States

🇺🇸

East West Eye Institute, Torrance, California, United States

🇺🇸

Andover Eye Associates, Andover, Massachusetts, United States

and more 3 locations
  • Prev
  • 1
  • 2
  • 3
  • 4
  • Next

News

No news found
© Copyright 2025. All Rights Reserved by MedPath